Novartis’s failed trial for cholesterol drug leads to broad biopharma stock selloff
marketwatch.com
08.09.2026 16:07
1 views
Along with several other drugmakers, Novartis has bet that lowering Lp(a) will cut the risk of sometimes fatal cardiovascular events.
Related stories
Heathrow and Gatwick among airports hit by air traffic control problems
bbc.co.uk · 08.09
Kraken Says Withdrawals Are Stuck as Funding Problems Hit 23 Services
finance.yahoo.com · 08.09
Tamarack Valley, Headwater Exploration agree $7.2bn all-stock merger
finance.yahoo.com · 08.09
Queen of Capital Gains: Pelosi Bets $3 Million on Bloom Energy — Then It Got Added to the S&P 500
finance.yahoo.com · 08.09
Micron Technology (MU) Rose on Elevated Demand for High-Bandwidth Memory
finance.yahoo.com · 08.09
Bloom Energy Surges 8% as S&P 500 Swaps It In for Trade Desk; TTD Stock Slips 2%
finance.yahoo.com · 08.09